Study shows vitamin D3 reduces risk of certain cancers
SAN DIEGO A new study looking at the relationship between vitamin D serum levels and the risk of colon and breast cancer across the globe has estimated the number of cases of cancer that could be prevented each year if vitamin D3 levels met the target proposed by researchers, the University of California, San Diego, announced last month.
Cancer prevention specialists at the Moores Cancer Center at UCSD estimate that 250,000 cases of colorectal cancer and 350,000 cases of breast cancer could be prevented worldwide by increasing intake of vitamin D3, particularly in countries north of the equator.
“For the first time, we are saying that 600,000 cases of breast and colorectal cancer could be prevented each year worldwide, including nearly 150,000 in the United States alone,” stated study co-author Cedrric Garland.
The paper, which looks at the dose-response relationship between vitamin D and cancer, was published in the August edition of the journal Nutrition Reviews.
The study combined data from surveys of serum vitamin D levels during winter from 15 countries. It is the first study to look at satellite measurements of sunshine and cloud cover in countries where actual blood serum levels of vitamin D3 had also been determined. The data were then applied to 177 countries to estimate the average serum level of a vitamin D metabolite of people living there.
The data revealed an inverse association of serum vitamin D with risk of colorectal and breast cancer. The researchers maintain that increasing vitamin D levels in populations, particularly those in northern climates, has the potential to both prevent and possibly serve as an adjunct to existing treatments for cancer.
“This could be best achieved with a combination of diet, supplements and short intervals – 10 or 15 minutes a day – in the sun,” Garland said. The serum level recommended by the study would correspond to intake of 2000 International Units per day of vitamin D3 for a meaningful reduction in colorectal cancer. The researchers recommend 2000 IU/day, plus, when weather allows, a few minutes in the sun with at least 40 percent of the skin exposed, for a meaningful reduction in breast cancer incidence, unless the individual has a history of skin cancer or a photosensitivity disease.
Relora survey finds 91 percent positive response
SALINAS, Calif. Next Pharmaceuticals on Tuesday released the results of an open label study on Relora. The study was conducted at The LaValle Metabolic Institute in Cincinnati, Ohio among 1,291 participants who suffered from stress, sleeplessness and/or stress-related eating.
According to the survey, 91 percent of the subjects reported Relora helped them relax, 90 percent reported Relora helped them have a restful sleep and 86 percent reported Relora helped prevent stress-related eating.
“This study demonstrates that Relora can be a successful adjunct for individuals who experience stress and anxiety, or who turn to food when dealing with tension,” stated Charles Kosmont, chief executive officer of Next Pharmaceuticals. “There are many methods to managing stress, and Dr. LaValle’s clinical study supports the fact that Relora is a natural, safe and effective approach with no toxic side effects.”
Relora consists of a patented blend of Magnolia bark extract and a proprietary blend of Phellodendron bark extract developed by Next Pharmaceuticals for the dietary supplement and functional food and beverage industries. Dr. James LaValle, author of Cracking the Metabolic Code, was the principal investigator of the study.
The subjects rated the efficacy of Relora on a 5-point scale. The product was considered effective for stress, restful sleep and stress-related eating if the subject rated the product 3 or higher. This study was developed as an open label, single center, clinical trial involving a minimum of 500 subjects with mild to moderate stress. Dr. LaValle enrolled both male and female subjects in the study as appropriate from patients at his clinic.
Matrixx announces plans to enter antacid market with Xcid
NEW YORK Matrixx revealed plans to enter the antacid market with a product called Xcid early in 2009 Wednesday, during the Roth Conference Presentation held here. According to the company, the acid neutralizing category is currently measured at around $500 million.
Xcid, featuring “from the makers of Zicam” on the packaging, will contain maximum strength quantities of calcium carbonate and magnesium hydroxide in a liquid format and will be launched with three flavors. Liquid antacids are considered highly efficacious among consumers, Carl Johnson, Matrixx president and chief executive officer, said, but there aren’t many good-flavored products currently on the market.
Matrixx will also be entering the oral care market in 2009, and will potentially target the analgesic sector for future product development.